Characterization of Dystrophin Deficient Rats: A New Model for Duchenne Muscular Dystrophy by Larcher, Thibaut et al.
Characterization of Dystrophin Deficient Rats: A New
Model for Duchenne Muscular Dystrophy
Thibaut Larcher, Aude Lafoux, Laurent Tesson, Severine Remy, Virginie
Thepenier, Virginie Franc¸ois, Caroline Le Guiner, He´licia Goubin, Maeva
Dutilleul, Lydie Guigand, et al.
To cite this version:
Thibaut Larcher, Aude Lafoux, Laurent Tesson, Severine Remy, Virginie Thepenier, et
al.. Characterization of Dystrophin Deficient Rats: A New Model for Duchenne Muscu-
lar Dystrophy. PLoS ONE, Public Library of Science, 2014, 9 (10), 13 p. <10.1371/jour-
nal.pone.0110371>. <hal-01190124>
HAL Id: hal-01190124
https://hal.archives-ouvertes.fr/hal-01190124
Submitted on 1 Sep 2015
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

Characterization of Dystrophin Deficient Rats: A New
Model for Duchenne Muscular Dystrophy
Thibaut Larcher1.", Aude Lafoux2.", Laurent Tesson3, Se´verine Remy3, Virginie Thepenier3,
Virginie Franc¸ois4, Caroline Le Guiner4,5, Helicia Goubin1, Mae´va Dutilleul1, Lydie Guigand1,
Gilles Toumaniantz2, Anne De Cian6, Charlotte Boix6, Jean-Baptiste Renaud6, Yan Cherel1{,
Carine Giovannangeli6, Jean-Paul Concordet6, Ignacio Anegon3*, Corinne Huchet2*
1 INRA, UMR703 APEX, Oniris, Atlantic Gene Therapies, Universite´ de Nantes, Oniris, E´cole nationale ve´te´rinaire, agro-alimentaire et de l’alimentation, Nantes, France,
2 INSERM, UMR 1087/CNRS 6291 Institut du Thorax, Universite´ de Nantes, Faculte´ des Sciences et des Techniques, Nantes, France, 3 INSERM, UMR 1064-Center for
Research in Transplantation and Immunology, ITUN, CHU Nantes, Universite´ de Nantes, Faculte´ de Me´decine, Nantes, France, 4 INSERM, UMR 1089, Atlantic Gene
Therapies, The´rapie ge´nique pour les maladies de la re´tine et les maladies neuromusculaires, Universite´ de Nantes, Faculte´ de Me´decine, Nantes, France, 5Genethon, Evry,
France, 6 INSERM, U1154, CNRS, UMR 7196, Muse´um National d’Histoire Naturelle, Paris, France
Abstract
A few animal models of Duchenne muscular dystrophy (DMD) are available, large ones such as pigs or dogs being expensive
and difficult to handle. Mdx (X-linked muscular dystrophy) mice only partially mimic the human disease, with limited chronic
muscular lesions and muscle weakness. Their small size also imposes limitations on analyses. A rat model could represent a
useful alternative since rats are small animals but 10 times bigger than mice and could better reflect the lesions and
functional abnormalities observed in DMD patients. Two lines of Dmd mutated-rats (Dmdmdx) were generated using TALENs
targeting exon 23. Muscles of animals of both lines showed undetectable levels of dystrophin by western blot and less than
5% of dystrophin positive fibers by immunohistochemistry. At 3 months, limb and diaphragm muscles from Dmdmdx rats
displayed severe necrosis and regeneration. At 7 months, these muscles also showed severe fibrosis and some adipose
tissue infiltration. Dmdmdx rats showed significant reduction in muscle strength and a decrease in spontaneous motor
activity. Furthermore, heart morphology was indicative of dilated cardiomyopathy associated histologically with necrotic
and fibrotic changes. Echocardiography showed significant concentric remodeling and alteration of diastolic function. In
conclusion, Dmdmdx rats represent a new faithful small animal model of DMD.
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Introduction
DMD is a severe X-linked muscular dystrophy due to mutations
of the DMD gene. It affects all voluntary muscles as well as the
heart and breathing muscles in later stages. Despite recent
promising new treatments the average life expectancy is severely
reduced in DMD patients and a better understanding of the
disease and faster evaluation of new treatments are needed [1].
Both large and small animal species deficient for dystrophin
have been described and have been extremely useful for pre-
clinical studies of DMD. Although they display more features of
the human clinical phenotype than mdx mice, large dystrophin-
deficient animals such as dogs [2] and pigs [3,4], suffer from
individual variability and are costly and time consuming. Mdx
mice [5,6] have the advantage of low maintenance costs. Sufficient
numbers of animals can also be easily characterized to reach high
statistical power. On the other hand, mdx mice exhibit only minor
clinical dysfunction [6] and their small size imposes limitations in
the analysis of several aspects of the disease. Although each animal
model has its own limitations, they have all been essential for the
development of treatment strategies that target dystrophin
absence, disease progression or muscle regeneration [7]. Never-
theless, new animal models are needed to help pre-clinical
research on DMD.
We hypothesized that the rat could represent a useful model of
DMD. One of its advantages of over mice is that its behavior is
much better characterized. Rats have finer and more accurate
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motor coordination than mice and exhibit a richer behavioral
display, including more complex social traits [8]. Rats have a
convenient size since they are 10 times larger than mouse but are
still a small laboratory animal model and allow studies with high
statistical power. Until recently, the rat model lacked genetic
engineering tools for introducing targeted genetic mutations. But
in the last years, we and others have used in rats sequence-specific
nucleases, such as meganucleases, zinc-finger nucleases, TALENs
and CRISPRs/Cas9, to efficiently generate precise gene mutations
[9–13].
To generate dystrophin-deficient rats, we generated TALENs
for Dmd that were microinjected in rat zygotes allowing generation
of two Dmdmdx rat lines. The muscles of both lines displayed
undetectable levels of dystrophin as evaluated by western blot
analysis and less than 5% of dystrophin positive fibers by
immunohistochemistry. At 3 months of age, forelimb, hindlimb
and diaphragm muscles showed severe fiber necrosis and a strong
regeneration activity. At 7 months of age, regeneration activity was
decreased and muscle showed abundant peri- and endomysial
fibrosis with some adipose tissue infiltration. Muscle strength and
spontaneous activity were decreased and fatigue was a prominent
finding of muscle function analysis. Cardiac muscle was also
affected with necrosis and fibrosis and showed signs of progressive
dilated cardiomyopathy. Echocardiography showed significant
concentric remodeling and alteration of diastolic function. These
lesions in skeletal muscle and heart closely mimic those observed in
DMD patients. These results indicate that Dmdmdx rats represent a
new invaluable small animal model for pre-clinical research on
DMD.
Materials and Methods
Animals
This study was approved by the Ethics Committee on Animal
Experimentation of the Pays de la Loire Region, France, in
accordance with the guidelines from the French National
Research Council for the Care and Use of Laboratory Animals
(Permit Numbers: CEEA-PdL-2011-45 and CEEA-PdL-
01579.01). All efforts were made to minimize suffering. Sprague-
Dawley (SD/Crl) rats were obtained from Charles River
(L’Arbresle, France). The rats were housed in a controlled
environment (temperature 2161uC, 12-h light/dark cycle). Before
blood collection, animals were anesthetized with a mixture of
ketamine (100 mg/kg, Imalgene, Merial, Lyon, France) and
xylazine (10 mg/kg, Rompun, Bayer, Leverkusen, Germany).
Rats were then sacrificed by intravenous administration of sodium
pentobarbital (300 mg, Dolethal, Vetoquinol UK Ltd, Bucking-
ham, UK). Just after sacrifice, the body weight (g) and the body
length (cm) of each rat were determined to define the body mass
index calculated as body weight/(body length)2 (g/cm2).
Design and production of TALE nucleases
TALE nucleases targeting Dmd exon 23 were designed to
recognize the following sites on Rat genome Assembly (Rnor_5.0 -
GCA_000001895.3/chrX: 51,878,333-52,510,293).
TCTGCAAAGCTCTTTGAAAGAGCAACAAAATGGCTT
CAACTATCTGAATGCCA.
TALE nucleases were produced, as previously described, by
unit assembly method adapted from Huang et al. 2011 [14–16].
For each TALE nuclease subunit, the fragment containing the 16
RVD segment was obtained from single unit vectors: A (NI), T
(NG), G (NN) and C (HD), derived from plasmids kindly provided
by the laboratory of Dr B. Zhang (Peking University, China). The
assembled TALE RVD (DMD-L: TCTGCAAAGCTCTTT-
GAAA; DMD-R: TGGCATTCAGATAGTTGA ) were sub-
cloned in the pVax vector containing the 17th half RVD, the
D152/+63 N- and C-terminal truncation points as described by
Miller et al. 2011 [17] and contained the wt Fok I catalytic
domains or FokI heterodimer-forcing mutations (ELD or KKR)
[18] that were constructed by site-directed mutagenesis starting
from Addgene plasmids 21872 et 21873 kindly made available by
the Joung lab. Assembled TALE nucleases DNAs were cloned into
the pVAX vector for mRNA production and in vitro cell
transfection.
In vitro assay of TALE nucleases
Each subunit of TALE nuclease (0.75 and 1.5 mg each) was
nucleofected into 4.105 C6 cells (Sigma) in 20 mL of V solution
using AMAXA FF137 program. Cells were grown into 12 well
dishes and collected 48 h after nucleofection. Genomic DNA was
extracted with E.Z.N.A. Tissue DNA Kit (OMEGA Biotek). The
genomic region encompassing the TALE nuclease target sites was
amplified with the primers listed below, typically using 50 ng of
genomic DNA, and phusion polymerase (New England Biolabs)
following manufacturer instructions. Unpurified PCR product
(10 mL out of 25 mL of PCR reaction) was supplemented with
10 mL of NEBuffer 2 (2X), melted, and annealed (5 min at 95uC,
95uC to 25uC at 20.5uC/30 sec, and 15 min at 4uC) to form
heteroduplex DNA. The annealed DNA was treated with 1.5 units
of T7 endonuclease I (New England BioLabs) for 20 min at 37uC
and run on a 2.4% agarose gel.
Off-target mutation analysis
Potential off-target sites were identified by bioinformatics using
the PROGNOS program [19] with parameters set for heterodi-
mer-forcing TALEN subunits and looking for pairs of potential
TALEN binding sequences with up to 6 mismatches to each
cognate target sequences of the TALEN pair separated by spacer
of 10 to 30 bp. Candidate off-target sites that were identified had
at least a total of 8 mismatches to the TALEN target sequence in
the DMD gene. We chose to further look for mutations at the 2
Figure 1. Targeted deletion in exon 23 of the rat Dmd gene via TALE nucleases. DNA cleavage takes place in the spacer sequence located
between TALEN DNA binding sequences indicated in blue. Dmdmdx rats carries a deletion of 11 nucleotides in exon 23 of the Dmd gene.
doi:10.1371/journal.pone.0110371.g001
TALEN Knockout Rat
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candidate sites lying on the X-chromosome because they could
potentially cosegregate with the DMD mutations and affect the
phenotype of the rats investigated. The candidate sites found on
X-chromosomes were TttCATTCAGcTAtTTGAAATGGGAA-
GACAGCACACTGATCCATTTttAAGAGgTTTGCAGc and
TCTatAAcGCcCTTTaAAAATGGAATAAGATCCTTTGCAA
GTGATTtAcCTATaTGAATGtgA with potential TALEN bind-
ing sites underlined and lowercase indicating mismatches to the
TALEN DMD target sequence. The presence of mutations was
tested using the T7 endonuclease E1 assay as detailed above using
specific primers for PCR listed below. No mutations could be
detected at candidate off-target sites from the X-chromosome in
tail DNA from 6 F0 (including the founder rats #61 and #71) and
8 F2 rats derived from founder rat #61 (including 4 DMD mutant
animals) using the T7 endonuclease 1 assay (data not shown).
Primer sequences:
DMDs CAAGTATGCATCGGTTAGTGTA
DMDas GCATCAATAACTTTGAGGGACT
XoffN1s CGAAATAGAGCTAGAATCCCCAGG
XoffN1as GTT TCC AAG GGA CAG ACA ACA CAG
XoffN2s CAG TCC TCT TTG CTC ATG TGC TAG
XoffN2as CCC TTG TGT GTG TGT GTG TGT ATG
In vitro transcription of TALE nucleases mRNA
As previously described, TALE nuclease plasmids were in vitro
transcribed to mRNA and polyadenylated using the mMessage
mMachine T7 Ultra kit (Ambion, Austin, TX) following the
manufacturer protocol and purified using the MegaClear Kit
(Ambion, Austin, TX), quantitated using a NanoDrop-1000
(Thermo Scientific) and stored at 280uC until use [12]. mRNAs
encoding each monomer of TALE nucleases for each target
sequence were mixed in TE 5/0.1 (5 mM Tris-Cl pH 7.5,
0.1 mM EDTA in RNase DNase free water) and stored at
280uC until use. mRNAs were diluted to the working concentra-
tion and kept on ice during one day micro-injection procedures
and then discarded.
Microinjection of rat one-cell embryos
Prepubescent females (4–5 weeks old) were super-ovulated with
pregnant mare serum gonadotropin (30 IU; Intervet, France) and
followed 48 hours later with human chorionic gonadotropin (20
IU; Intervet, France) before breeding. Zygotes were collected for
subsequent microinjection using a previously published procedure
[12,20]. Briefly, a mixture of TALE nucleases mRNA was
microinjected into the cytoplasm of fertilized one-cell stage
embryos. Microinjected embryos were maintained under 5%
CO2 at 37uC until reimplantation. Surviving embryos were then
implanted immediately in the oviduct of pseudo-pregnant females
(0.5 dpc) and allowed to develop until term.
Analysis of Dmd mutation events
DNA from embryos or neonates was extracted from tail biopsy
following treatment with Proteinase K as previously described
[12]. To analyze mutations, we first used PCR followed by the T7
endonuclease I assay (as described above in the in vitro analysis of
mutations) to identify rats carrying mutations and PCR products
were sequenced.
Dystrophin messenger analysis
Total RNA was extracted from muscles with TRIzol reagent
(Invitrogen) and 500 ng of this RNA was reverse transcribed using
random primers (Invitrogen) and M-MLV reverse transcriptase
(Invitrogen). Detection of the Dystrophin mRNA was done by 25
cycles of PCR1 followed by 30 cycles of PCR2 using 1 ml of ADNc
or 1 ml of PCR1, 2,5 U of GoTaq DNA polymerase (Promega),
1,5 mM of MgCl2 and 0,2 mM of each following primers (PCR1:
Table 1. Rat weight and size as well as isolated muscles weight and heart characteristics of Dmdmdx male rats.
Age 3 month-old 7 month-old
WT Dmdmdx WT Dmdmdx
Rat characteristics
Body weight (g) 456.0621.2 409.4618.9 749.7645.9 501.6630.1*
Body length (cm) 25.960.4 25.560.3 28.960.4 27.160.4*
Body mass index (g/cm2) 0.6860.02 0.6360.02 0.8960.03 0.6860.03*
Muscle weight
Tibialis Anterior (mg) 751.8641.2 822.9650.2 1009.2657.1 773.1658.1*
Tibialis Anterior (mg/g) 1.6560.02 2.0060.07 1.3560.07 1. 5460.06*
Extensor Digitorum Longus (mg) 200.6610.4 205.0610.5 257.2614.0 193.2615.9
Extensor Digitorum Longus (mg/g) 0.4460.01 0.5060.01 0.3460.02 0.3860.01
Soleus (mg) 184.966.5 199.9610.8 206.268.2 189.0613.7
Soleus (mg/g) 0.4160.01 0.4960.02 0.2860.01 0.3860.02
Heart characteristics
Weight (mg) 1379.5684.7 1732.26271.1 2049.8672.6 1766.3684.4*
Weight (mg/g) 3.0260.13 4.2160.58 2.7560.11 3.5560.16*
p/LV (%) 56.060.1 44.960.03 1 43.161.8 35.863.9 1
n 5 5 4 5
body mass index calculated as body weight/(body length)2; (g/cm2).
Values are means 6 SEM; *: p,0.05 vs wild-type controls (WT); 1: p,0.0001 vs WT. n, numbers of rats.
doi:10.1371/journal.pone.0110371.t001
TALEN Knockout Rat
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ex20ratDyst-F TCA GAC AAG CCT CAG AAC AA and
ex26ratDyst-R AGTTTTATCCAAACCAGCCT annealing
50uC; PCR2:ex22ratDyst-F AAT GCG CTA TCA AGA GAC
AA and ex24ratDyst-R TCT GCA CTG TTT GAG CTG TT
annealing 55uC). Final PCR products were migrated on an 1.5%
agarose gel and revealed with ethidium bromide staining (Fig.
S6).
Western blot analysis
Total proteins from muscle were extracted using 400 mL of
RIPA extraction buffer containing protease inhibitors (Roche) and
ground with TissueLyser II (Qiagen). 50 mg of protein extracts
were loaded on a 3–8% Tris-Acetate Precast polyacrylamide gel of
NuPAGE Large Protein blotting kit (Invitrogen). After Red
Ponceau staining, membranes were incubated with two different
mouse anti-Dystrophin antibodies: NCL-DYS2 (1:100, Novocas-
tra), MANEX 1011C (1:100, MDA Monoclonal Antibody
Resource) [21] and with an anti-GAPDH antibody (1:10000,
Imgenex). Detection was performed using a secondary anti-mouse
IgG HRP-conjugated antibody (1:2000, Dako) or secondary anti-
goat IgG HRP-conjugated antibody (1:2000, Dako). Immunoblots
were revealed with ECL Western blotting substrate (Pierce) and
exposed to ECL-Hyperfilm (Amersham).
Histopathological evaluation
After gross examination, tibialis cranialis, extensor digitorum
longus, biceps femoris muscles of the hindlimb, soleus and biceps
brachii muscles of the forelimb, diaphragm and heart were
sampled and divided in two parts. Furthermore, tibialis cranialis,
extensor digitorum longus, soleus and heart were weighted. The
first part was frozen and 8-mm-thick serial sections were cut for
immunohistology and histoenzymology assays, the second part was
fixed in 10% neutral buffered formalin, embedded in paraffin wax,
and 5-mm-thick sections were cut and routinely stained with
hematoxylin eosin saffron for histopathological evaluation. Addi-
tional sections were stained with Picrosirius red stain for collagen,
Gomori’s trichrome and Alizarin red staining for calcium. All
lesions were reported by a skilled pathologist certified by the
European College of Veterinary Pathology.
Immunohistochemistry and histoenzymology assays
Immunohistochemical analysis involved the use of immunoper-
oxidase techniques on frozen sections. MANDYS110 clone 3H10,
provided by the Wolfson Centre for Inherited Neuromuscular
Disease, NCL-DYSB and NCL-DYS2 (Novocastra Laboratories,
Newcastle on Tyne, UK) mouse monoclonal antibodies were used
for dystrophin protein detection (1:50 for each ones). Other
Figure 2. No dystrophin expression was detected in cardiac and skeletal muscles of Dmdmdx rats. (A) Male 7 month-old rats of line 61,
wild-type littermate controls (WT) and Dmdmdx were sacrificed and biopsies from tibialis cranialis muscles (TC) and hearts (H) were harvested.
Western-blot of total proteins (50 mg) was incubated with NCL-DYS2 and Manex1011C monoclonal antibodies (C-terminal and exons 10/11 epitopes,
respectively). This revealed undetectable levels of the 427 kDa dystrophin band in line 61 Dmdmdx rats. Muscle from a GRMD dog (GD) was used as
negative control and samples from WT rats were used as positive controls. Staining with an anti-GAPDH polyclonal antibody validated equal protein
loadings. (B–E) Heart and biceps femoris muscles from the same wild-type (B and C) and Dmdmdx rats (D and E) were assessed for dystrophin
expression using immunohistochemistry with Mandys110 monoclonal antibody (against exons 38–39 epitope). Compared to the subsarcolemmal
expression of dystrophin in wild-type muscles, no dystrophin was detected in Dmdmdx rats except for the presence in skeletal muscle of only rare
scattered revertant positive fibers (arrowheads). Immunolabelling of dystrophin (B–E) Bar = 100 mm.
doi:10.1371/journal.pone.0110371.g002
TALEN Knockout Rat
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primary antibodies used were IVD31A9 (1:50, Developmental
Studies Hybridoma Bank, Iowa City, IA), NCL-g-Sarc (1:10,
Novocastra Laboratories) and NCL-DRP2 (1:60, Novocastra
Laboratories) for alpha-sarcoglycan, gamma-sarcoglycan, and
utrophin detection respectively, NCL-MHCd (1:20, Novocastra
Laboratories) for developmental myosin heavy chain isoform, anti-
complement 5b-9 (1:250, Calbiochem, Strasbourg, France) and
anti-CD3 (1:100, Dako, Glostrup, Denmark) for lymphocytes.
Briefly, transverse cryosections were incubated in PBS with 5%
normal goat serum (Dako) for 1 hour at room temperature. They
were then incubated with primary antibody in 5% rat serum
overnight at 4uC and with biotinylated secondary antibodies
(E433, 1:300, Dako) in PBS with 5% rat serum for 1 hour. Bound
antibodies were detected either with streptavidin (P397; Dako) and
DAB Liquid Substrate (Dako) for immunoperoxidase. Fiber type
was determined using histochemical myosin-ATPase reaction after
preincubation at pH 4.2, 4.35, and 10.4 as previously described
[22].
Histomorphometry
Morphometric analysis was done using a digital camera (Nikon
DXM 1200; Nikon Instruments, Badhoevedorp, the Netherlands)
combined with image-analysis software (NIS; Nikon). To deter-
mine the proportion of dystrophin-positive fibers in the biceps
femoris muscle of 3 and 7 month-old Dmdmdx rats (5 individuals in
each group), a total of 1,000 fibers were counted in sections
immunolabelled with Mandys110 antibody and the percentage of
fibers expressing dystrophin was determined. To determine the
percentage of MyoHCDev fibers, at least 1,000 fibers were
numbered on randomly selected microscopic fields. Fiber size
was documented measuring minimal Ferret diameter on at least
250 fibers (292661 per sample), on randomly selected microscopic
fields in picrosirius red-stained sections. Fibrosis was determined as
the ratio of areas rich in collagen using specific picrosirius staining
on the total muscle area in an overall cross section. Repeatability
was tested by the same operator measuring five times the same
Figure 3. Severe and progressive muscle changes in Dmdmdx rats. Biceps femoris muscle was sampled at 3 and 7 month-old from wild-type
littermate controls (WT) and Dmdmdx rats. Compared to controls (A), 3 month-old Dmdmdx rat skeletal muscles (B) displayed individual fiber necrosis
(open arrowhead) associated with foci of small newly regenerating centronucleated fibers (arrow). In addition, 7 month-old muscles displayed a
progessive replacement of fibers by fibrosis (*) and fat (black arrowhead) tissue (C). The regenerative activity was assessed using a specific antibody
against the Myosin Heavy Chain developmental isoform (MyoHCDev). No regenerative activity was observed in control rats (D) whereas newly
regenerating fibers were numerous in Dmdmdx rats (E) with a decrease in their number with age (F). Histological changes were quantified. Fiber
minimal Ferret diameter was measured. A global switch towards lower sized fibers was observed in the fiber size distribution in mutated rats
compared to controls at 3 and 7 month of age (G–H). Hemalun eosin saffron staining (A–C), immunolabelling of Myosin Heavy Chain developmental
isoform (MyoHCDev) (D–F). Bar = 100 mm (A–C) and 200 mm (D–F).
doi:10.1371/journal.pone.0110371.g003
TALEN Knockout Rat
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sample. The intra-assay variations coefficients were always lower
than 5%.
Serum creatine phosphokinase levels
Blood was collected just before sacrifice under anesthesia.
Creatine phosphokinase (CK) activity was determined at the
Central Laboratory of the National Veterinary School (E.N.V) at
Nantes using a commercial kit (LaRoche Diagnostic). Results were
expressed as CK levels [23].
Skeletal muscle function
The in vivo tests were performed in the same sequence for each
rat, with equivalent time of rests between the tests [23].
Grip test. Rats were placed with their forepaws or four paws
on a grid and were gently pulled backward until they released their
grip [24]. A grip meter (Bio-GT3, BIOSEB, France), attached to a
force transducer, measured the peak force generated. Five tests
were performed in sequence with a short latency between each
test, and the reduction in strength between the first and the last
determination was taken as an index of fatigue [24]. Results are
expressed in grams (g) and normalized to the body weight (g/g).
Actimeter. The motor behavior was examined with an open
field actimeter [25]. For this analysis, rats were individually placed
in an automated photocell activity chamber (Letica model LE
8811, Bioseb, France) which consists of a plexiglass chamber
(45 cm645 cm650 cm) surrounded by two rows of infrared
photobeams. The first row of sensors was raised at a height of
3 cm for measuring horizontal activity and the second row placed
above the animal for vertical activity. The spontaneous motor
activity was measured for 5 min using a movement analysis system
(Bioseb, France), which dissociates resting and ambulatory time (s),
distance traveled (cm), stereotyped, and rearing movements.
Echocardiography
Two-dimensional (2-D) echocardiography was performed on
rats using a MyLab70 Family - Ultrasound Systems – Esaote with
a CA129 transducer [26]. In order to look for possible structural
remodelling, the left ventricular end-diastolic diameter and the
Figure 4. Progressive myofiber replacement by fibrotic and fat tissue in Dmdmdx rats. A picrosirius red staining specific for fibrosis was
performed on biceps femoris (A–C), respiratory (D–F) and heart muscle (G–I) samples obtained from wild-type littermate controls (WT) and 3 month-
old and 7 month-old Dmdmdx rats. Compared to control rats (left panel), a progressive increase in the amount of fibrotic tissue (black arrowhead) was
noticed in 3 (mid panel) and 7 month-old Dmdmdx rats (right panel). Note the focal presence of fat tissue infiltration (open arrowhead). In the heart,
fibrosis was most marked in papillary muscle of the left ventricle (LV), in the septum and in the ventricular subepicardic area. Picrosirius red staining.
Bar = 100 mm (A–F) and 1 mm (G–I).
doi:10.1371/journal.pone.0110371.g004
TALEN Knockout Rat
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free wall end-diastolic thickness were measured during the diastole
from long and short-axis images obtained by M-mode echocar-
diography. Furthermore, the systolic function was assessed by the
ejection fraction, while transmitral flow measurements of ventric-
ular filling velocity were obtained using pulsed Doppler, with an
apical four-chamber orientation. Thus, Doppler–derived mitral
deceleration time, the early diastolic (E), the late diastolic (A) and
the ratio E/A were obtained to assess diastolic dysfunction
associated to an evaluation of the isovolumetric relaxation time.
To avoid bias in the analysis, experiments were done in a blind
fashion.
Statistics
Differences between means were analyzed by unpaired
Student’s t-test. When the Student test was not applicable a Mann
Whitney test was used. All analyses were performed using
SigmaStat 3.1 software (Logi Labo, Paris, France) and Xlstat
(Addinsoft, Paris, France). The data are presented as mean 6
S.E.M. with the significance level set at p,0.05.
Results
Generation of Dmd mutated rats
We generated a pair of TALENs targeting exon 23 of the rat
Dmd gene in order to generate rats with Dmd mutations
comparable to that of the mdx mouse (Fig. S1) [11,14]. The
TALE DNA-binding domains were fused either to the wild-type
FokI nuclease domain that can form homodimers or to mutated
forms (so called ELD or KKR mutants for each monomer) that
can only form heterodimers and thus will have less potential off-
target effects. Plasmids encoding wild-type or ELD/KKR
TALENs were transfected into rat C6 cells at different doses
and were found to induce mutations in dose dependent fashion as
evidenced by the PCR-T7 endonuclease I assay (Fig. S1). Even if
that the wild-type pair was more effective at inducing mutations,
we chose to use the heterodimeric ELD/KKR TALEN pair for
the sake of improved specificity.
The mRNAs of each ELD/KKR TALEN monomer were
microinjected into the cytoplasm of 387 rat zygotes, 320 were
viable and 294 were transferred into pseudopregnant females, as
previously described (Table S1) [11,12]. This resulted in the 88
Figure 5. Dmdmdx rats are characterized by muscle weakness and by a decrease in a spontaneous activity. Forelimb grip test and
locomotor activity of Dmdmdx rats were analyzed at the age of 3 months. Compared to wild-type littermate controls (WT), Dmdmdx rats were
characterized by muscle weakness and showed a lower strength in absolute values (A) and when normalized to body weight (B). Dmdmdx rats showed
fatigue with a decreased force grip across the five pulls, and significant values are obtained for the two last trials that were reduced to ,70% when
compared to Trial 1. At 3 months, when compared to WT, Dmdmdx rats were less active and the number of movements (C), the total distance travelled
(C), the time of activity (D) and the number of rearing (D) were significantly lower. Values are means 6 SEM; *p,0.05 vs WT; 1: p,0.05 vs Trial 1.
doi:10.1371/journal.pone.0110371.g005
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newborns and among them 11 showed mutations (3.74% of the
transferred zygotes and 12.5% of newborns). These results are
similar to our previous ones injecting other engineered sequence-
specific nucleases and thus Dmd TALENs did not trigger embryo
toxicity and allowed to induce Dmd gene mutations as expected
[9–12].
The Dmd mutations observed in newborn rats were deletions
ranging from 1 to 24 bp and insertions of a few nucleotides
Figure 6. Structural remodelling and altered diastolic function in hearts of Dmdmdx rats. Echocardiography was performed on 3 month-old
Dmdmdx rats. The structural remodeling and the systolic and diastolic functions were assessed respectively by Two-dimensional (2-D)
echocardiography and pulsed Doppler (n = 6 for each condition); Values are mean 6 SEM; *p,0.05). (TM mode: Time movement mode; LV: Left
ventricular; E/A ratio: early diastolic (E)/late diastolic (A) ratio).
doi:10.1371/journal.pone.0110371.g006
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(Table S2). Two of the newborns presented mutations that did
not disrupt the open reading frame and were not further analyzed.
In the other newborns, the mutations disrupted the open reading
frame and resulted in premature stop codons. Some animals with
Dmd mutations detected in tail DNA did not transmit the
mutation to their offspring, most likely because it was not present
in the germ line due to late activity of TALENs after injection,
while several of them transmitted the mutations to the offspring in
a Mendelian manner: two of these rat lines were further analyzed
(lines 61 and 71). Both lines displayed the same muscle
anatomopathological and functional characteristics and therefore
only line 61, hereafter called Dmdmdx is presented in this report.
Dmdmdx mutation is a deletion of 11 bp in exon 23 leading to a +1
frame shift and premature stop codon 81 bp after the mutation
(Fig. 1 and Table S2).
Female offspring of mutant founders that carried the mutation
did not show premature death and were indistinguishable from
wild-type littermate controls (Fig. S2 A). X-linked DMD mainly
affects boys and we have therefore only characterized male
Dmdmdx rats in this study. When compared to wild-type littermate
controls of the same ages, Dmdmdx rats are smaller and less heavy
(Table 1 and Fig. S2 B). As illustrated by the increase in weight
with age, the growth of Dmdmdx rats is significantly altered as soon
as 4 weeks of development (Fig. S2 C).
Founder 61 and its offspring were analyzed for potential off
target mutations at other loci. The closest homologous sequences
to the ones recognized by Dmd TALENs showed eight mismatch-
es. We chose to further look for mutations at the 2 candidate sites
located on the X-chromosome because they could potentially
cosegregate with the Dmd mutations and affect the mutant rat
phenotype (Table S2). They were analyzed no mutations could
be detected by T7 endonuclease I assays (data not shown).
Altogether, these results indicate that rat lines with a specific
disruption of the Dmd coding frame by premature stop codons
were successfully generated.
Analysis of dystrophin expression
Western blot analysis of dystrophin expression in tibialis
cranialis and cardiac muscles was performed using two antibodies
directed against epitopes located at the C terminus and within
exons 10–11. No expression of dystrophin or of a truncated
dystrophin could be detected in muscle tissues analyzed from Dmd
mutated animals (Fig. 2A).
Immunohistological analysis of biceps femoris and cardiac
muscles using mouse monoclonal antibodies directed against three
different epitopes (located within exons 11–12, 38–39 and exon 78)
revealed rare scattered dystrophin positive fibers in all Dmd
mutated animals (Fig. 2B–E for epitope within exons 38–39 and
data not shown). Dystrophin positive fibers in biceps femoris of
mutated animal of line 61 after immunolabelling represented
4.960.8% (n= 5) of total number of fibers. Such dystrophin
positive fibers are frequently observed in animal models of
dystrophin deficiency [26]. The exact mechanism involved in
the generation of the so-called revertant myofibers remains poorly
understood.
The dystrophin-associated protein complex is severely affected
in skeletal muscle of DMD patients. We therefore examined the
expression of alpha- and gamma- sarcoglycan, two proteins of the
dystrophin-associated complex. The expression of alpha-sarcogly-
can (Fig. S3 A, B) and gamma (data not shown) was weak and
scarce compared to the systematic expression in myofibers of wild-
type rats [27]. Altogether, these results indicate that Dmdmdx rats
are bona fide dystrophin deficient animals.
Histopathological evaluation of muscles
Before histopathological evaluation, skeletal muscle and heart
weights were measured in 3 and 7 month-old rats. Fast muscles
tibialis anterior and extensor digitorum longus muscles reached
significantly lower weights, of around 25% less, in 7 month-old
Dmdmdx rats compared to wild-type controls (Table 1). In
contrast, the slow soleus skeletal muscle was not significantly
affected. The loss of skeletal muscle mass that was detected is
consistent with the lower body weight of Dmdmdx rats (Fig. S2 C)
and indicates that muscular atrophy takes place in Dmdmdx rats,
preferentially in fast muscles. The heart weights were slightly
higher at 3 months and significantly lower at 7 months in Dmdmdx
rats compared to littermates (Table 1). At 3 months, hearts of
Dmdmdx rats were markedly dilated with left ventricular wall
thinning and increased diameter of the ventricular cavity. Ratio
between left ventricle wall thickness and ventricular cavity
diameter was significantly decreased compared to age-related
wild-type littermate controls at 3 and 7 months (Table 1). All
Table 2. Comparison of pathological and functional characteristics between patients and animal models of Duchenne disease.
DMD patient GRMD dog DMD pig HFMD cat Mdx mouse Dmdmdx rat
Muscle histopathology
Revertant fibers 1 to 3% ,1% ND ND 5% 5%
Necrotic fibers 0.5 to 3.5% 2% absent present 5% .10%
Regeneration ND 15% ND present 10% 10%
Calcification mild mild to
marked
ND severe mild absent
Fibrosis marked present present diaphragm
mainly
late & mainly
diaphragm
marked
Lipomatosis severe absent absent absent absent mild
Cardiomyopathy marked, major
cause of death
mild absent present absent or late marked
Muscle function
Strength reduction marked marked ND ND mild marked
Locomotion severely impaired impaired impaired ND normal impaired
doi:10.1371/journal.pone.0110371.t002
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together these changes in heart morphology were indicative of a
progressive dilated cardiomyopathy in Dmdmdx rats.
Histopathological evaluation of tibialis cranialis, extensor
digitorum longus, biceps femoris, biceps brachii, soleus and
diaphragm skeletal muscles and heart was performed at 3 and 7
month-old. Similar severe lesions were present in all examined
striated skeletal muscles and were characterized by excessive fiber
size variation with some large rounded hypertrophic fibers and
clusters of small centronucleated regenerating fibers (Fig. 3 and
Fig. S4). Numerous individual necrotic fibers appeared fragment-
ed or contained invading inflammatory cells (Fig. 3 and Fig. S4),
some being CD3-positive lymphocytes (data not shown). No
calcium deposit was noticed after HES or Alizarin red stainings.
ATPase staining revealed a predominance of type 1 fibers with
perturbation of the normal random distribution of muscle fiber
types, abnormal fiber grouping and presence of some type 2C
fibers, described to be observed in case of a regenerating process
after fiber necrosis (Fig. S5). These lesions were accompanied by a
patchy increase in endomysial connective tissue at 3 months and a
marked endomysial and perimysial fibrosis at 7 months (Fig. 3 A–
C). The main lesions observed in striated skeletal muscles were
quantified by histomorphometry on the biceps femoris muscle. The
mean minimal Ferret diameter was 41.1620.9 mm vs
54.7616.7 mm and 45.0622.5 mm vs 54.7618.5 mm, respectively
at 3 and 7 months in Dmdmdx rat versus age-related controls (n = 5
in each group) showing a significant decrease in individual fiber
size in Dmdmdx rats (p,0.0001) (Fig. 3 G, H). This decreased
diameter was illustrated by the modal value that was 30 to 40 mm
in 3 and 7 month-old Dmdmdx rats (19.561.6% and 19.562.6%,
respectively), whereas it corresponded to 50 to 60 mm in wild-type
littermate controls (19.561.6% and 19.763.8%, respectively).
The smallest fibers (with diameter less than 10 mm) represented
5.468.0% and 1.160.6% in 3 and 7 month-old Dmdmdx rats
compared to the lower percentage in age-related control rats
(0.560.7% and 0.060.0%, respectively). The strong regenerative
activity suggested by this last result was assessed by examining
expression of developmental myosin heavy chain isoform
(MyoHCDev), a marker specific to developing and regenerating
myofibers. Abundant MyoHCDev positive fibers were observed in
biceps femorismuscles of 3 and 7 month-old Dmdmdx rats vs control
rats (13.166.7% and 10.264.4%, respectively, illustrating a slight
decrease with time) and were absent in muscles of wild-type
littermate controls (Fig. 3 D–F). In addition, utrophin expression
was found in fiber clusters with continuous membrane immuno-
labelling, also suggestive of regenerative processes as previously
described in other models [28] (data not shown).
The accumulation of connective tissue in biceps femoris,
diaphragm and cardiac muscles was confirmed using a specific
picrosirius staining in 7 month-old Dmdmdx rats and was associated
mostly with muscle fiber focal replacement by adipose tissue
(Fig. 4). In the heart, fibrosis was most prominent in papillary
muscle of the left ventricle (Fig. 4 G–I), in the septum and in the
ventricular subepicardic area.
Total fibrosis was assessed by measuring the area occupied by
connective tissue in transverse sections of biceps femoris. Connec-
tive tissue represented 16.964.7% and 24.368.7% in Dmdmdx rats
compared to 6.763.2% and 6.462.3% in control rats at 3 and 7
months of age, respectively, demonstrating a significant effect of
the mutation on total fibrosis (p,0.0001).
In the cardiac muscle, individual fiber necrosis associated with
inflammatory cell infiltration and fibrosis predominated at 3 and 7
months in Dmdmdx rats (Fig. S4 C). Fibrous connective tissue
represented 8.064.9% and 15.767.9% of the total cardiac muscle
area in Dmdmdx rats compared to 4.363.1% and 3.461.4% in
wild-type littermate controls at 3 and 7 months, respectively. The
increase in the fibrotic area from 3 to 7 months in Dmdmdx rats was
significant (p,0.0001).
Dmdmdx rats have a high level of serum creatine kinase
In DMD patients, muscle damage is characterized by an
increase of creatine kinase (CK) activity in the serum. In Dmdmdx
rats, CK levels showed a 10-fold augmentation when compared to
wild-type littermate controls (CK (U.L21). At 3 month-old, CK
levels were 19456620 in Dmdmdx rats (n = 5) and 185617 in wild-
type rats (n = 5) (p,0.05); At 7 month, these levels were 39656817
in Dmdmdx rats (n = 5) and 5886397 in wild- type rats (n = 5) (p,
0.05). These results suggest an increased fragility of muscle
membrane and confirmed that Dmdmdx rats develop a dystrophic
pathology.
Significant muscle weakness in Dmdmdx rats
To examine whether the absence of dystrophin affected muscle
function, we performed a grip test on 3 month-old Dmdmdx rats. A
significant decrease in forelimb grip strength indicated a gener-
alized alteration in the whole body muscular performance. As
illustrated in Fig. 5 (A, B), at the first trial to the grip a 30%
weaker force was exerted by Dmdmdx rats compared to wild-type
littermates. Furthermore, while control rats maintain the same
force over five successive pulls, the grip force of Dmdmdx rats
decreased significantly and became 70% weaker than that of
control rats. Therefore, Dmdmdx rats presented a decreased grip
strength test demonstrating muscle weakness, a typical sign
observed in DMD patients [24,29].
Decrease in the spontaneous activity in Dmdmdx rats
Behavioral and locomotor measurements are important param-
eters that help to define the phenotypes of animal models with
neuromuscular disorders such as muscular dystrophies [25]. These
assessments were done in an open field plexiglass chamber
equipped with multiple photocell receptors and emitters. At the
age of 3 months, Dmdmdx rats were less active than control
littermates and the number of movements, the total distance
travelled and the time of activity were significantly lower
respectively 2167%; 3867%; 1765% lower in Dmdmdx than in
wild-type littermate controls (p,0.05) (Fig. 5C, D). Furthermore,
the horizontal activity as rearing was also significantly impaired
and reduced by 5568% (p,0.05) in Dmdmdx rats compared to
wild-type littermate controls (Fig. 5D). These data demonstrate
that motor activity and locomotor behavior are severely affected in
Dmdmdx rats.
Modification of the heart function in Dmdmdx rats
At 3 months, Dmdmdx rat and wild-type control littermates
showed the same heart rate values under anaesthesia
(HRWT=221613 bpm and HRDmd
mdx= 219612 bpm) (Fig. 6).
The echocardiographic investigations revealed structural remod-
eling with a significant decrease in the LV end-diastolic diameter
(EDDWT=7.460.4 mm and EDDDmd
mdx= 6.360.2 mm)
associated with thickening of the LV end-diastolic anterior
wall in Dmdmdx rats (EDAWWT=1.660.1 mm and
EDAWDmd
mdx= 2.360.1 mm). These observations suggest the
presence of a concentric remodeling in Dmdmdx rats heart at the
age of 3 months. We did not observe any change in systolic
function as ejection fraction (EFWT= 82.363.3% and
EFDmd
mdx=83.362.6%) and shortening fractions (SFWT=
44.364.4% and SFDmd
mdx=47.862.8%; data not shown). How-
ever, diastolic dysfunction markers were observed. We observed
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changes in E/A ratio (E/AWT=1.760.1 and E/ADmd
mdx=
1.260.1), in Doppler–derived mitral deceleration time (DTWT=
34.361.3 msec and DTDmd
mdx=54.261.8 msec) and in isovolu-
metric relaxation time (IRTWT=23.360.9 msec and IRTDmd
mdx=
34.261.5 msec) (Fig. 6). These data demonstrate structural remod-
eling and altered diastolic function in hearts of Dmdmdx rats.
Discussion
In this study, we describe the generation and the full
characterization of a novel dystrophin deficient rat model (Dmdmdx
rats) with phenotypic properties very close to the human DMD
pathology.
DMD is the most common neuromuscular disorder, accounting
for approximately 30% of muscular dystrophy patients [30–32].
The responsible gene is located in the short arm of the X
chromosome, Xp21, and contains 14 kbp of dystrophin protein
coding sequence split in 79 exons. The primary molecular
characteristic of DMD patients is the absence of dystrophin
protein in skeletal and cardiac muscles. The present results show
that dystrophin was undetectable by western blot in skeletal
muscles of Dmdmdx rats. In agreement, immunohistological
analysis demonstrated that dystrophin is undetectable in 95% of
fibers in skeletal muscles and only some revertant fibers were
visible, as in DMD patients and other animal models of DMD
[27]. Immunostaining and western blot analyses demonstrated
that dystrophin was also undetectable in hearts of Dmdmdx rats.
The absence of dystrophin, as encountered in DMD patients, leads
to absence of the dystro-associated protein complex, instability of
the muscle cell membrane and uncontrolled influx of calcium.
This initiates a set of downstream pathological processes that
ultimately lead to loss of muscle cell proteins, myofiber damage
and progressive muscle wasting [33]. Similar to muscle damages in
DMD patients, Dmdmdx rats are characterized by a loss of skeletal
muscle mass, muscle fiber necrosis, increased variation in fiber size
due to the simultaneous presence of hypertrophic fibers and small
centronucleated regenerating fibers, infiltration by inflammatory
cells, regenerative activity and interstitial fibrosis in skeletal
muscles. All these signs of tissue changes observed in limb and
forelimb skeletal muscles are correlated with a dramatic increase of
serum creatine kinase activity in 3 and 7 month-old Dmdmdx rats.
As observed in DMD patients but not in mdx mice [34], fibrosis
was severe in all skeletal muscle examined as well as in cardiac
muscle of Dmdmdx rats (Fig. 4). It is well described in dystrophin
deficient skeletal myofibers that Ca2+ homeostasis alteration is
pivotal in the initiation of the fiber damages [35,36]. In skeletal
muscle from Dmdmdx rats at 3 and 7 months, while severe lesions
were present no calcification was observed. Thus it will be
interesting to further investigate calcium regulation in Dmdmdx rat
skeletal muscles.
Consistent with histomorphological muscle damages, at 3 and 7
months of age, Dmdmdx rats exhibit muscle dysfunction with
decrease in muscle force and reduced locomotor activity. The
clinical manifestations of Dmdmdx rats evaluated at 3 and 7 months
of age were progressive with gradual loss of body weight and
muscle mass (mainly of fast twitch muscles such as tibialis anterior)
as well as in necrosis and degeneration of skeletal muscle fibers
including fundamental muscles such as the diaphragm. Addition-
ally, Dmdmdx rats showed a progressive dilated cardiomyopathy as
indicated by morphological analyses, concentric structural remod-
eling and diastolic dysfunction. Since the majority of DMD
patients die from cardiac failure [37] the cardiac dysfunction
described in Dmdmdx rats is an important feature of this new DMD
model.
All skeletal and cardiac lesions as well as functional deficits are
important features of the rat Dmdmdx model since they are similar
to those of patients. It will be interesting to study the disease onset
in this new model as was previously studied in the mdx mouse, in
particular to identify the early prenecrotic stages. Importantly, the
changes observed between the two time points of this study i.e 3
and 7 month-old showed a progressive evolution of the pathology
in this rat model, in the same manner than those described in
DMD patients. Therefore, Dmdmdx rats will be useful for pre-
clinical assessment of new therapies. In particular, as analyses of
dystrophin mRNA in the muscles of Dmdmdx rats showed that the
mutated exon 23 was transcribed (Fig. S6). Dmdmdx rats could
therefore be used for the evaluation of DMD treatment using an
exon skipping approaches.
The use of TALENs targeting the rat Dmd gene was efficient at
introducing Dmd mutations. Other types of gene-specific nucleases
are available, such as ZFNs and more recently CRISPRs/Cas9,
that have also been used successfully in rats [9–13,38]. Therefore,
the generation of new rat models of neuromuscular disease using
artificial sequence-specific nucleases now appears very promising.
While this manuscript was in preparation, dystrophin-deficient
rats generated with CRISPR/Cas9 targeting exon 2 and exon 16
were reported [38]. The phenotype of the corresponding F0 rats
showed characteristics similar to the Dmdmdx rats in skeletal muscle
although progression of the disease was not documented. In the
heart, in contrast, even though morphological changes were
reported in some 3-month old F0 animals, they were not found
statistically significant. The difference between the two models
could be due to differences in genetic backgrounds (Wistar-
Imamichi inbred vs Sprague-Dawley outbred strain for Dmdmdx)
or to mosaicism of Dmd mutations in F0 animals studied in the
latter report.
The genetic heterogeneity and body size of the Golden
Retriever Muscular Dystrophy dog model (GRMD) is closer to
humans than the mice (Table 2). Therefore, GRMD is an
important animal model for DMD. However, one major
disadvantage is the large heterogeneity in the clinical phenotypes
of GRMD dogs that makes the functional evaluation of potential
therapies difficult. The mdx mouse has been important as a DMD
model for development of gene therapy approaches. Murine
models as mdx, mdx5cv, mdx52 will continue to provide important
findings for the basic study of pathogenesis and development of
therapies but they do not show significant muscle weakness or
cardiac alterations nor any of the skeletal or cardiac muscle lesions
developing at late time points in DMD patients, such as fibrosis
and muscular atrophy. In contrast, it was shown that mdx/
mTRKO mice, combining the mdx mutation with deletion of the
gene for the RNA component of telomerase, show skeletal muscle
dysfunction and progressive dilated cardiomyopathy as a result of
shortened telomers and accelerated depletion of stem cell
reservoirs [39,40]. Given the much aggravated skeletal and
cardiac muscle phenotype of Dmdmdx rats compared to mdx mice,
it will be interesting to look for any difference in telomere
dynamics or stem cell biology between these two closely related
species that could be involved.
In summary, our study shows that Dmdmdx rats represent a
promising model to further elucidate mechanisms of DMD and to
test novel therapies, in particular those aiming to curtail heart
alterations and skeletal muscle disease progression.
Supporting Information
Figure S1 Mutation rates of TALE nucleases targeting
exon 23 of the rat Dmd gene. The mutation rates induced by
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TALE nuclease were determined using T7 endonuclease assay in
C6 cells transfected with indicated amounts of rat Dmd TALE
nucleases expression vectors. Homodimeric (WT, 0.75 mg each)
and heterodimeric (EDL/KKR; 0.75 mg and 1.5 mg each)
TALEN pairs (DMD-L+DMD-R) have been evaluated as well
as left and right part of the TALEN pair (1.5 mg). The expected
sizes of digested fragments are indicated near the gel. The rates of
insertion and deletion mutations (indels) detected are indicated
below each lane. The TALEN binding sites in exon 23 are
indicated in blue.
(TIFF)
Figure S2 Growth of Dmdmdxrats. Newborns at day 2 (A).
While wild-type littermate controls (WT) and Dmdmdx rats were
indistinguishable after birth, Dmdmdx rats were noticeably smaller
at the age of 16 weeks (B). Body weight values from WT and
Dmdmdx rats from 4 to 12 weeks postnatal (C). Values are mean 6
SEM; *p,0.05 Dmdmdx vs WT, analyzed by unpaired t test.
(TIF)
Figure S3 The absence of dystrophin in skeletal muscle
fibers is associated with a strong reduction in alpha-
sarcoglycan expression in Dmdmdxrats. Biceps femoris
muscle samples were assessed for the expression of proteins of
the dystrophin associated protein complex by immunohistochem-
istry. Compared to the generalized subsarcolemmal expression of
alpha-sarcoglycan in wild-type littermate control (WT) rats (A),
only some fibers expressed the protein in 7 month-old Dmdmdx rats
(B). Bar = 100 mm.
(TIF)
Figure S4 Muscle changes were present in all striated
muscle including skeletal, respiratory and cardiac ones
in Dmdmdx rats at 7 month-old. In extensor digitorum longus
(A) and diaphragm (B) muscles, hypercontracted hyalin giant fibers
(u) and individual necrotic fibers (open arrowhead), sometimes
surrounded by some inflammatory cells (#), were associated with
foci of small regenerative centro-nucleated fibers (arrow). Some
muscle fibers were replaced by fibrotic (*) and fat (black
arrowhead) tissue. In cardiac muscle (C), individual fiber necrosis
(open arrowhead) elicited some inflammatory cell infiltration (#).
Focal thick bundles of fibrotic tissue surround cardiomyocytes (*).
Hemalun eosin saffron staining (A–C). Bar = 100 mm.
(TIF)
Figure S5 Abnormal fiber type pattern in Dmdmdx rats.
Compared to wild-type littermate control (WT) rats, biceps femoris
muscles from 7-month-old Dmdmdx rats were characterized by type
1 predominance and grouping (type 1 fibers in black) and
abnormal presence of type 2C (intermediate grey staining, open
arrowhead). ATPase staining, pH 4.35. Bar = 100 mm.
(TIF)
Figure S6 Dystrophin messenger RNA expression in
skeletal muscles and hearts of Dmdmdx rats. Dystrophin
mRNA was detected by nested RT-PCR from exon 22 to 24 in
tibialis cranialis muscles and in hearts sampled in 7 month-old
Dmdmdx rats and wild-type control littermates. No skipping of the
mutated exon 23 was detected in muscles from Dmdmdx rats.
(TIF)
Table S1 Efficacy of generation of Dmd mutants by
TALE nuclease microinjection.
(DOC)
Table S2 Dmd mutations and potential off target
sequences analyzed in founder animals.
(DOC)
Acknowledgments
Yan Cherel died during the course of the study. This manuscript is
dedicated to his memory.
Author Contributions
Conceived and designed the experiments: YC CG JPC IA CH. Performed
the experiments: TL AL LT SR VT VF CLG HG MD LG GT ADC CB
JBR YC CG JPC IA CH. Analyzed the data: TL AL LT SR VT VF CLG
HG MD LG GT ADC CB JBR YC CG JPC IA CH. Contributed to the
writing of the manuscript: IA CH.
References
1. Jarmin S, Kymalainen H, Popplewell L, Dickson G (2014) New developments in
the use of gene therapy to treat Duchenne muscular dystrophy. Expert Opin Biol
Ther 14: 209–230.2.
2. Sharp NJ, Kornegay JN, Van Camp SD, Herbstreith MH, Secore SL, et al.
(1992) An error in dystrophin mRNA processing in golden retriever muscular
dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics
13: 115–121.
3. Klymiuk N, Blutke A, Graf A, Krause S, Burkhardt K, et al. (2013) Dystrophin-
deficient pigs provide new insights into the hierarchy of physiological
derangements of dystrophic muscle. Hum Mol Genet 22: 4368–4382.
4. Hollinger K, Yang CX, Montz RE, Nonneman D, Ross JW, et al. (2014)
Dystrophin insufficiency causes selective muscle histopathology and loss of
dystrophin-glycoprotein complex assembly in pig skeletal muscle. FASEB J 28:
1600–1609.
5. Bulfield G, Siller WG, Wight PA, Moore KJ (1984) X chromosome-linked
muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci U S A 81: 1189–
1192.
6. Partridge TA (2013) The mdx mouse model as a surrogate for Duchenne
muscular dystrophy. FEBS J 280: 4177–4186.
7. Nakamura A, Takeda S (2011) Mammalian models of Duchenne Muscular
Dystrophy: pathological characteristics and therapeutic applications. J Biomed
Biotechnol. 2011: 184393.
8. Jacob HJ, Kwitek AE (2002) rat genetics: attaching physiology and pharmacol-
ogy to the genome. Nat Rev Genet 3: 33–42.
9. Me´noret S, Fontanie`re S, Jantz D, Tesson L, Thinard R, et al. (2013)
Generation of Rag1-knockout immunodeficient rats and mice using engineered
meganucleases. FASEB J 27: 703–711.
10. Geurts AM, Cost GJ, Freyvert Y, Zeitler B, Miller JC, et al. (2009) Knockout
rats via embryo microinjection of zinc-finger nucleases. Science 325: 433.
11. Remy S, Tesson L, Menoret S, Usal C, De Cian A, et al. (2014) Efficient gene
targeting by homology-directed repair in rat zygotes using TALE nucleases.
Genome Res, in press.
12. Tesson L, Usal C, Me´noret S, Leung E, Niles BJ, et al. (2011) Knockout rats
generated by embryo microinjection of TALENs. Nat Biotechnol 29: 695–696.
13. Li D, Qiu Z, Shao Y, Chen Y, Guan Y, et al. (2013) Heritable gene targeting in
the mouse and rat using a CRISPR-Cas system. Nat Biotechnol 31: 681–683.
14. Auer TO, Duroure K, De Cian A, Concordet JP, Del Bene F (2014) Highly
efficient CRISPR/Cas9-mediated knock-in in zebrafish by homology-indepen-
dent DNA repair. Genome Res 24: 142–153.
15. Piganeau M, Ghezraoui H, De Cian A, Guittat L, Tomishima M, et al. (2013)
Cancer translocations in human cells induced by zinc finger and TALE
nucleases. Genome Res 23: 1182–1193.
16. Huang P, Xiao A, Zhou M, Zhu Z, Lin S, et al. (2011) Heritable gene targeting
in zebrafish using customized TALENs. Nat Biotechnol 29: 699–700.
17. Miller JC, Tan S, Qiao G, Barlow KA, Wang J, et al. (2011) A TALE nuclease
architecture for efficient genome editing. Nat Biotechnol 29: 143–148.
18. Doyon Y, Vo TD, Mendel MC, Greenberg SG, Wang J, et al. (2011) Enhancing
zinc-finger-nuclease activity with improved obligate heterodimeric architectures.
Nat Methods 8: 74–79.
19. Fine EJ, Cradick TJ, Zhao CL, Lin Y, Bao G (2014) An online bioinformatics
tool predicts zinc finger and TALE nuclease off-target cleavage. Nucleic Acids
Res42: e42.
20. Geurts AM, Cost GJ, Re´my S, Cui X, Tesson L, et al. (2010) Generation of
gene-specific mutated rats using zinc-finger nucleases. Methods Mol Biol 597:
211–225.
21. Bartlett RJ, Stockinger S, Denis MM, Bartlett WT, Inverardi L, et al. (2000) In
vivo targeted repair of a point mutation in the canine dystrophin gene by a
chimeric RNA/DNA oligonucleotide. Nat Biotechnol 18: 15–622.
TALEN Knockout Rat
PLOS ONE | www.plosone.org 12 October 2014 | Volume 9 | Issue 10 | e110371
22. Dubowitz V, Brooke MH (1985) Muscle Biopsy: a Modern Approach. Saunders:
London: 335–356.
23. Carre-Pierrat M, Lafoux A, Tanniou G, Chambonnier L, Divet A, et al. (2011)
Pre-clinical study of 21 approved drugs in the mdx mouse. Neuromuscul Disord
21: 313–327.
24. De Luca AM (2008) Use of grip strength meter to assess the limb strength of mdx
mice. SOP DMD_M.2.2.001.
25. Kanneboyinna N (2008) Behavioural and Locomotor Measurements Using
Open Field Animal Activity Monitoring System. SOP DMD_M.2.1.002.
26. Arechavala-Gomeza V, Kinali M, Feng L, Guglieri M, Edge G, et al. (2010)
Revertant fibres and dystrophin traces in Duchenne muscular dystrophy:
implication for clinical trials. Neuromuscul Disord 20: 295–301.
27. Muller J, Vayssiere N, Royuela M, Leger ME, Muller A, et al. (2001)
Comparative evolution of muscular dystrophy in diaphragm, gastrocnemius and
masseter muscles from old male mdx mice. J Muscle Res Cell Motil 22: 133–
139.
28. Lin S, Gaschen F, Burgunder JM (1998) Utrophin is a regeneration-associated
protein transiently present at the sarcolemma of regenerating skeletal muscle
fibers in dystrophin-deficient hypertrophic feline muscular dystrophy. Neuro-
pathol Exp Neurol 57: 780–790.
29. Desguerre I, Christov C, Mayer M, Zeller R, Becane HM, et al. (2009) Clinical
heterogeneity of duchenne muscular dystrophy (DMD): definition of sub-
phenotypes and predictive criteria by long-term follow-up. PLoS One 4: e4347.
30. Hoffman EP, Brown RH Jr, Kunkel LM (1987) Dystrophin: the protein product
of the Duchenne muscular dystrophy locus. Cell 51: 919–928.
31. Koenig M, Monaco AP, Kunkel LM (1988) The complete sequence of
dystrophin predicts a rod-shaped cytoskeletal protein. Cell 53: 219–228.
32. Muntoni F, Torelli S, Ferlini A (2003) Dystrophin and mutations: one gene,
several proteins, multiple phenotypes. Lancet Neurol 12: 731–40. Review.
33. Nowak KJ, Davies KE (2004) Duchenne muscular dystrophy and dystrophin:
pathogenesis and opportunities for treatment. EMBO Rep 5: 872–876. Review.
34. Klingler W, Jurkat-Rott K, Lehmann-Horn F, Schleip R (2012) The role of
fibrosis in Duchenne muscular dystrophy. Acta Myol 31: 184–95.
35. Whitehead NP, Yeung EW, Allen DG (2006) Muscle damage in mdx
(dystrophic) mice: role of calcium and reactive oxygen species. Clin Exp
Pharmacol Physiol 33: 657–662. Review.
36. Allen DG, Gervasio OL, Yeung EW, Whitehead NP (2010) Calcium and the
damage pathways in muscular dystrophy. Can J Physiol Pharmacol 88: 83–91.
37. Kieny P, Chollet S, Delalande P, Le Fort M, Magot A, et al. (2013) Evolution of
life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine
de Kepper centre between 1981 and 2011. Ann Phys Rehabil Med. 56: 443–
454.
38. Nakamura K, Fujii W, Tsuboi M, Tanihata J, Teramoto N, et al. (2014)
Generation of muscular dystrophy model rats with a CRISPR/Cas system. Sci
Rep 4: 5635–56.
39. Sacco A, Mourkioti F, Tran R, Choi J, Llewellyn M, et al. (2010) Short
telomeres and stem cell exhaustion model Duchenne muscular dystrophy in
mdx/mTR mice. Cell 143: 1059–1071.
40. Mourkioti F, Kustan J, Kraft P, Day JW, Zhao MM, et al. (2013) Role of
telomere dysfunction in cardiac failure in Duchenne muscular dystrophy. Nat
Cell Biol. 15: 895–904.
TALEN Knockout Rat
PLOS ONE | www.plosone.org 13 October 2014 | Volume 9 | Issue 10 | e110371
